US Earnings Financial Results SEC Filings — April 30, 2026

30-04-2026

IMAX reported Q1 2026 revenues of $81,379 thousand, down 6.1% YoY from $86,667 thousand, with declines in all segments including technology rentals (-14.0% to $16,624 thousand), image enhancement and maintenance services (-4.3% to $48,584 thousand), technology sales (flat/slight decline to $13,414 thousand), and finance income (-10.4% to $2,757 thousand). Gross margin fell 13.9% to $45,811 thousand and operating income dropped 40.5% to $9,951 thousand due to higher costs in maintenance services and R&D, but net income attributable to common shareholders more than doubled to $4,226 thousand ($0.08 basic EPS) from $2,327 thousand ($0.04), aided by SG&A reduction and credit loss reversal. Operating cash flow decreased to $4,029 thousand from $6,951 thousand YoY.

• · Cash and cash equivalents decreased QoQ to $145,995 thousand from $151,168 thousand.
• · Revolving credit facility borrowings increased to $46,702 thousand from $34,577 thousand (QoQ).
• · Net cash used in investing activities $6,927 thousand, mainly equipment investments.
• · Total shareholders’ equity stable at $427,646 thousand.
• · Weighted average diluted shares outstanding 56,392 thousand (up from 54,969 thousand YoY).

30-04-2026

Ford Motor Company reported Q1 2026 consolidated revenues of $43,253 million, up 6.4% YoY from $40,659 million, with vehicles/parts/accessories rising to $37,644 million (+5%) and used vehicles surging to $1,147 million (+67%). Net income attributable to Ford rose sharply to $2,548 million from $471 million YoY. However, net cash from operating activities declined 64% to $1,316 million from $3,679 million, cash equivalents dropped 24% QoQ to $17,649 million from $23,356 million, and total assets decreased 2.2% QoQ to $282,434 million.

• · Inventories increased 8.3% QoQ to $16,537 million from $15,285 million.
• · Dividends declared reduced to $611 million ($0.15 per share) in Q1 2026 from $1,212 million ($0.30 per share) in Q1 2025.
• · Purchases of common stock $311 million in Q1 2026.
• · Net cash used in investing activities $771 million in Q1 2026 vs provided $210 million in Q1 2025.

30-04-2026

For Q1 2026, Anika Therapeutics reported revenue of $29,612, up 13% YoY from $26,168, driven by a 30% increase in gross profit to $18,997 due to a 8% decline in cost of revenue. However, operating expenses rose 29% YoY to $24,485, primarily from a 38% surge in SG&A to $17,772, resulting in a wider operating loss of $5,488 (up 28% YoY) and net loss of $5,056. Cash and equivalents fell 29% QoQ to $41,020 amid $8,690 in stock repurchases and $4,846 in operating cash use.

• · Weighted average basic shares outstanding declined to 13,531 from 14,297 YoY.
• · Stockholders' equity decreased QoQ to $133,901 from $143,465.
• · Net cash used in operating activities was $4,846 in Q1 2026 vs $130 in Q1 2025.
• · Company repurchased 775 shares in Q1 2026 vs 241 in Q1 2025.

30-04-2026

For the three months ended March 31, 2026, NorthWestern Energy Group reported total revenues of $497,570 up 6.6% YoY from $466,630, with electric revenues increasing 7.9% to $362,054 and gas revenues up 3.3% to $135,516. However, operating expenses rose 12.2% to $383,459 driven by a 31.5% jump in operating and maintenance costs to $74,540, resulting in operating income declining 8.5% to $114,111 and net income dropping 17.6% to $63,456 (EPS $1.03 vs $1.25). Cash from operations improved 3.8% to $159,414, while capex increased to $116,080 from $92,124.

• · Dividends declared per common share increased to $0.67 from $0.66 YoY.
• · Total shareholders' equity grew to $2,908,884 from $2,885,740 at Dec 31, 2025.
• · Interest expense, net, rose to $39,916 from $36,511 YoY.

30-04-2026

Glaukos Corp reported net sales of $150,571 thousand for the three months ended March 31, 2026, up 41.2% YoY from $106,664 thousand, with gross profit increasing 42.3% to $117,232 thousand. However, total operating expenses rose 33.1% YoY to $137,088 thousand, leading to an operating loss of $19,856 thousand (4.0% improvement YoY) but a net loss widening to $19,783 thousand from $18,146 thousand. Cash and equivalents grew to $104,249 thousand QoQ from $90,813 thousand, with net cash used in operations improving to $12,526 thousand from $18,521 thousand YoY.

• · Short-term investments decreased to $172,436 thousand from $187,947 thousand QoQ.
• · Inventory slightly declined to $62,384 thousand from $63,564 thousand QoQ.
• · Total assets remained flat at $893,326 thousand vs $893,487 thousand QoQ.
• · Stockholders' equity increased to $670,928 thousand from $656,155 thousand QoQ.
• · Net cash provided by investing activities was $10,504 thousand vs used $36,948 thousand YoY.
• · Proceeds from exercise of stock options: $19,330 thousand in Q1 2026.

30-04-2026

Ford Motor Credit Co LLC's total assets decreased 2.4% quarter-over-quarter to $158,541M as of March 31, 2026 from $162,453M at December 31, 2025, driven by lower finance receivables net ($117,049M, down 2.3%). Net income for Q1 2026 rose 59% YoY to $675M from $424M in Q1 2025, with cash from operating activities up 61% to $1,294M; however, shareholder’s interest fell 2.3% to $14,467M due to a $950M distribution, debt decreased 2.7% to $137,531M, and provision for credit losses increased 23% YoY to $172M.

• · Allowance for credit losses increased to $937M from $911M QoQ.
• · Distributions declared $950M in Q1 2026 vs $200M in Q1 2025.
• · Net cash decrease in cash, cash equivalents, and restricted cash was $1,340M in Q1 2026 vs $1,816M decrease in Q1 2025.

30-04-2026

QDRO Acquisition Corp., a SPAC, completed its IPO in Q1 2026, raising net proceeds of $196M and depositing $200M into the Trust Account, resulting in total assets of $201.3M as of March 31, 2026, up dramatically from $0.4M at year-end 2025. However, the company reported a net loss of $145,685 for the quarter due to $165K in general and administrative costs, with shareholders' deficit widening to $7.1M from $66K amid accretion of $15.2M related to redeemable shares.

• · IPO involved sale of 20,000,000 Units; 750,000 founder shares forfeited.
• · Promissory note – related party repaid in full ($240,315 outstanding at Dec 31, 2025).
• · Deferred offering costs cleared post-IPO.
• · Trading symbols: QADRU (Units), QADR (Class A Shares), QADRW (Warrants) on NASDAQ.

30-04-2026

KLA Corp reported strong Q3 FY2026 results with total revenues of $3,415.1 million, up 11.5% YoY from $3,063.0 million, driven by product revenue growth of 10.3% to $2,640.3 million and service revenue up 15.8% to $774.8 million; net income rose 10.2% YoY to $1,201.0 million. For the nine months ended March 31, 2026, revenues increased 10.5% YoY to $9,921.9 million and net income surged 21.3% to $3,467.7 million. However, cash and cash equivalents declined 14.0% to $1,787.0 million from $2,078.9 million at June 30, 2025, reflecting significant share repurchases of $1.72 billion and dividend payments of $752.5 million.

• · Operating cash flow for 9M FY2026: $3,236.6 million, up from $2,916.9 million prior year.
• · Capital expenditures for 9M FY2026: $286.7 million.
• · Inventories increased to $3,437.0 million from $3,212.1 million at Jun 30, 2025 (+7%).
• · Long-term debt stable at $5,887.1 million.
• · Net cash used in investing activities 9M FY2026: $1,017.0 million.

30-04-2026

Titan International reported net sales of $505.1M for Q1 2026, up 3% YoY from $490.7M, with gross profit increasing 4% to $71.4M. However, a $25.1M restructuring and impairment expense led to an operating loss of $13.8M, compared to $11.8M profit in Q1 2025, resulting in a net loss attributable to common shareholders of $24.2M ($0.38 per share) versus $0.6M loss last year. Cash and equivalents decreased to $171.3M from $202.9M at year-end, with operating cash use worsening to $46.5M.

• · Total assets increased to $1,714.8M from $1,672.7M QoQ.
• · Total liabilities rose to $1,213.3M from $1,151.0M QoQ.
• · Titan shareholders' equity declined to $494.9M from $514.4M QoQ.
• · Accounts receivable increased $99.6M QoQ to $338.5M.
• · Capital expenditures were $13.3M in Q1 2026, down from $15.0M YoY.

30-04-2026

Amazon reported strong Q1 2026 results with total net sales increasing 16.6% YoY to $181,519M, driven by 11.5% growth in net product sales to $71,304M and 20.2% in net service sales to $110,215M; net income surged 76.7% YoY to $30,255M with diluted EPS at $2.78. Operating cash flow rose 53% YoY to $26,032M, though investing cash flow deteriorated to -$64,212M due to sharply higher capex of $44,203M (up 76.7% YoY). Total assets grew to $916,630M, but inventories declined slightly to $36,534M.

• · Long-term debt increased to $119,074M from $65,648M as of Dec 31 2025.
• · TTM net cash from operating activities reached $148,531M, up from $113,903M.
• · Diluted shares used: 10,874M in Q1 2026 vs 10,793M in Q1 2025.

30-04-2026

Hippo Holdings Inc. reported Q1 2026 total revenue of $121.5M, up 10% YoY from $110.3M, driven by 13% growth in net earned premium to $98.9M and higher net investment income, leading to net income of $7.1M versus a $47.7M loss attributable to Hippo in Q1 2025. However, commission income declined 12% to $12.7M, losses and LAE remained elevated at $47.5M despite a 49% YoY drop, and total investments decreased to $423.9M from $445.9M QoQ. Total assets grew 8% QoQ to $2,061.9M, with stockholders' equity at $448.7M, and operating cash flow turned positive at $8.5M.

• · Net income per share basic $0.27 for Q1 2026 vs ($1.91) for Q1 2025.
• · Unearned premiums increased to $615.3M from $579.7M QoQ.
• · Cash, cash equivalents, and restricted cash at $304.8M as of March 31, 2026, up from $250.1M at start of period.

30-04-2026

RF Acquisition Corp III, a SPAC, reported net income of $725,986 for the three months ended March 31, 2026 and $673,033 for the six months ended, driven by $825,232 in other income from interest on the Trust Account ($403,232) and fair value changes ($422,000), despite operating losses of $99,246 and $152,199 respectively from general and administrative costs. The company completed its IPO, funding the Trust Account to $100,403,232 (10,000,000 shares at $10.04 redemption value) and increasing total assets to $101.4M from $113K at September 30, 2025, with shareholders' equity rising to $899K. Cash stood at $933K post-IPO, but net cash used in operations was $168K for the six months.

• · Net cash used in operating activities for six months: $168,184
• · Promissory note – related party repaid: $159,374 (six months)
• · Accretion of carrying value to redemption value: $5,701,876
• · Ordinary shares subject to possible redemption: 10,000,000 shares at $10.04 per share

30-04-2026

Canadian Pacific Kansas City Ltd (CP) reported Q1 2026 total revenues of $3,701 million, down 2% YoY from $3,795 million, with freight revenues declining 3% to $3,628 million as most segments decreased (e.g., Forest products -17%, Coal -12%) while Grain grew 11% to $871 million. Operating income fell 4% to $1,258 million and net income dropped 7% to $845 million (EPS $0.94 vs $0.98), though cash from operations was $976 million and the company ramped up share repurchases to $680 million from $347 million. Comprehensive income rose sharply to $1,398 million from $881 million, boosted by a $538 million foreign currency translation gain.

• · Weighted-average basic shares decreased to 896.8 million from 933.2 million YoY due to repurchases.
• · Dividends declared per share increased to $0.228 from $0.190.
• · Additions to properties decreased to $664 million from $711 million.
• · Long-term debt increased to $21,883 million as at March 31, 2026 from $19,948 million at Dec 31, 2025.

30-04-2026

Bausch Health Companies Inc. reported Q1 2026 revenues of $2,524 up 11.7% YoY from $2,259, primarily driven by product sales growth of 12.3% to $2,500. However, a $1,426 goodwill impairment resulted in an operating loss of $950 versus prior year income of $276, and net loss attributable to the company widened to $1,423 from $58. Cash provided by operating activities edged up 9% to $230 while total assets declined to $24,498 from $26,366 at year-end.

• · Goodwill decreased to $9,807 from $11,271 at Dec 31 2025 due to $1,426 impairment.
• · Shareholders' deficit widened to $(2,059) from $(554) at Dec 31 2025.
• · Long-term debt (current + non-current) totaled $20,764 at Mar 31 2026 versus $20,817 at Dec 31 2025.
• · Small acquisition with $87 fair value of consideration transferred and $65 identifiable net assets.

30-04-2026

Chipotle Mexican Grill reported Q1 2026 total revenue of $3,088,242 up 7.4% YoY from $2,875,253, primarily driven by 7.5% growth in food and beverage revenue to $3,072,730, while delivery service revenue remained nearly flat at $15,512. However, income from operations declined 17.1% to $397,063 due to sharp increases in labor (12.1%), food costs (9.0%), and other operating costs (15.8%), resulting in net income of $302,824, down 21.7% YoY. The company repurchased $755,256 in common stock, contributing to a drop in shareholders' equity to $2,407,635 and cash equivalents to $246,636.

• · Net cash used in financing activities: $747,490 in Q1 2026 vs $585,174 in Q1 2025 due to higher stock repurchases.
• · Operating cash flow increased 17% YoY to $651,350.
• · Capital expenditures (purchases of leasehold improvements, property and equipment): $180,332 in Q1 2026 vs $144,810 in Q1 2025.
• · Chipotle Rewards liability ending balance: $67,340 as of Mar 31 2026.

30-04-2026

Acadia Healthcare reported Q1 2026 revenue of $828,802 thousand, up 7.6% YoY from $770,505 thousand, driven by 14.2% growth in acute inpatient psychiatric facilities to $470,653 thousand and 6.3% in residential treatment centers, while specialty treatment facilities declined 6.5% to $128,116 thousand and comprehensive treatment centers grew modestly 2.5% YoY. However, net income attributable to ACHC fell 51% to $4,105 thousand from $8,374 thousand, with EPS dropping to $0.05 from $0.09, due to higher legal settlements expense ($13,751 thousand vs $3,504 thousand), professional fees, and interest expense. Operating cash flow improved sharply to $61,531 thousand from $11,477 thousand.

• · Medicaid revenue increased to 60.7% of total ($503,406 thousand) from 55.9% ($430,814 thousand), while commercial payer mix declined to 22.4% ($185,926 thousand) from 25.0%.
• · Accounts receivable, net increased QoQ to $471,752 thousand from $440,604 thousand as of December 31, 2025.
• · Capital expenditures were $76,564 thousand in Q1 2026, down significantly from $174,631 thousand in Q1 2025.

30-04-2026

Benchmark Electronics Inc reported Q1 2026 sales of $677,280 thousand, up 7.2% YoY from $631,764 thousand, with gross profit rising 9.6% to $69,234 thousand and net income surging 257% to $13,023 thousand, aided by lower restructuring charges of $3,747 thousand versus $11,417 thousand. Operating cash flow improved 49.3% to $47,028 thousand YoY. However, inventories increased 5.3% QoQ to $507,447 thousand, shareholders' equity declined 0.3% QoQ to $1,096,501 thousand, and advance payments from customers fell to $110,966 thousand from $115,545 thousand QoQ.

• · Accounts receivable decreased to $375,902 thousand from $391,101 thousand QoQ.
• · Accounts payable increased to $451,146 thousand from $403,222 thousand QoQ.
• · Dividends declared $6,101 thousand in Q1 2026.
• · Share repurchases totaled $5,799 thousand in Q1 2026.
• · Goodwill stable at $192,116 thousand, allocated $154,014 thousand to Americas and $38,102 thousand to Asia.

30-04-2026

Moelis & Co reported revenues of $319,780 for Q1 2026, up 4.2% YoY from $306,593, with operating income increasing 9.7% to $40,496. However, net income attributable to the company declined 23.5% to $38,433 from $50,268, resulting in diluted EPS of $0.48 versus $0.64 YoY. Total assets fell to $1,289,194 from $1,740,685 QoQ, driven by sharp drops in cash and investments, while operating cash flow deteriorated to negative $278,798 from negative $165,480 YoY.

• · Compensation payable decreased to $64,752 from $439,394 QoQ.
• · Treasury stock purchases of $117,270 in Q1 2026.
• · Dividends declared at $0.65 per share of Class A common stock.

30-04-2026

Alphabet Inc. reported Q1 2026 revenues of $109,896M, up 21.8% YoY from $90,234M, with net income surging 81.1% YoY to $62,578M driven by strong Google Cloud growth of 63.4% to $20,028M and Google advertising up 15.5% to $77,253M. However, Google Network revenues declined 3.9% YoY to $6,971M, Other Bets fell 8.7% to $411M, and the company recorded hedging losses of $180M versus gains of $260M prior year. Total assets expanded to $703,919M, bolstered by acquisitions totaling $33,621M net.

• · Operating cash flow increased 26.7% YoY to $45,790M.
• · No stock repurchases in Q1 2026 versus $15,068M in Q1 2025.
• · Long-term debt rose to $77,501M from $46,547M as of Dec 31, 2025.
• · Goodwill increased to $57,774M from $33,380M, reflecting acquisitions.
• · Dividends declared at $0.21 per share, up from $0.20 prior year.
• · Net cash used in investing activities widened to $63,389M from $16,194M.

30-04-2026

Southern Power Company's 10-Q filing dated April 30, 2026 covers the quarter ended March 31, 2026, providing metadata including filer status as a Large Accelerated Filer, shares outstanding of 1,000 (par value $0.01 per share), and listings of junior subordinated notes and senior notes traded on NYSE. The document includes a table of contents pointing to unaudited financial statements and MD&A starting on page 9, along with an extensive glossary of terms related to Southern Company subsidiaries and operations. No specific quarterly financial performance metrics such as revenue, earnings, or period-over-period comparisons are detailed in the provided excerpt.

• · Southern Power Company designated as Large Accelerated Filer.
• · Financial statements (unaudited) begin on page 9; MD&A on page 83.
• · Glossary includes terms like AFUDC, ARO, CWIP, HLBV, IRA, PTC, and references to Vogtle Owners (Georgia Power, OPC, MEAG Power, Dalton).

30-04-2026

CRH reported Q1 2026 total revenues of $7,370M, up 9.1% YoY from $6,756M, with strong growth in Americas Materials Solutions (+21.5% to $2,724M) and International Solutions (+5.3% to $2,978M), while Americas Building Solutions declined slightly (-0.8% to $1,668M). However, net loss widened to $(180)M from $(98)M YoY, resulting in comprehensive loss attributable to CRH of $(272)M versus $105M income last year, amid higher impairments and operating cash use of $(616)M (improved from $(659)M). Cash and equivalents fell to $3,240M from $4,096M at year-end, with total assets stable at $58,167M.

• · Equity method investments decreased to $487M from $502M (Dec 2025) and $732M (Mar 2025).
• · Long-term debt $16,071M at Mar 31 2026, down slightly from $16,478M (Dec 2025).
• · Capex purchases of PP&E and intangibles $601M in Q1 2026 vs $645M prior year.
• · Share repurchases $332M in Q1 2026.

30-04-2026

Atlantis Glory Inc. reported zero revenue for Q1 2026, consistent with Q1 2025, while net loss widened slightly to $(9,227) from $(8,954), driven by higher general and administrative expenses of $9,227 versus $8,954 YoY. Total liabilities increased to $219,855 as of March 31, 2026 from $210,628 at year-end 2025, with stockholders' deficit deepening to $(219,855). The company remains cashless at $0, fully funded by $18,347 in related party advances to cover $18,347 in operating cash usage.

• · Amount due to related party increased to $213,455 as of Mar 31 2026 from $195,108 at Dec 31 2025.
• · Accrued expenses decreased to $6,400 from $15,520 QoQ.
• · Cash and cash equivalents remained at $0 at period end.
• · EPS basic and diluted $(0.00) for both Q1 2026 and Q1 2025.
• · Total assets $0 as of Mar 31 2026 and Dec 31 2025.

30-04-2026

For the three months ended March 31, 2026, PREFORMED LINE PRODUCTS CO (PLPC) reported net sales of $176,278 thousand, up 18.7% YoY from $148,541 thousand, driven by higher volumes, with gross profit increasing 13.5% to $55,220 thousand. However, operating income grew modestly 4.5% to $13,716 thousand, net income attributable to shareholders declined 8.6% to $10,524 thousand (diluted EPS $2.14 vs $2.33), and comprehensive income attributable to shareholders dropped sharply to $9,099 thousand from $18,311 thousand due to a $1,425 thousand foreign currency translation loss. Operating cash flow improved 6.9% to $6,047 thousand, though net cash decreased $13,937 thousand amid higher capex and financing outflows.

• · Consolidated product mix Q1 2026: Energy 71% (up from 69% YoY), Communications 24% (down from 25%), Special Industries 5% (down from 6%).
• · Allowance for credit losses increased to $6,293 thousand at March 31, 2026 from $5,797 thousand at Dec 31, 2025.
• · Capital expenditures $9,993 thousand in Q1 2026 (down from $10,976 thousand YoY).
• · Purchase of common shares for treasury from related parties: $8,286 thousand in Q1 2026 (up from $881 thousand YoY).

30-04-2026

Pilgrim's Pride Corporation reported net sales of $4,532,633 thousand for the three months ended March 29, 2026, up 1.6% YoY from $4,463,009 thousand. However, gross profit declined 37.8% to $345,490 thousand amid higher cost of sales, resulting in operating income dropping 59.8% to $162,556 thousand and net income attributable to PPC falling 65.7% to $101,423 thousand (basic EPS $0.43 vs $1.25). Operating cash flow improved 11.0% to $140,818 thousand, though cash and equivalents decreased to $542,415 thousand.

• · Net sales by region Q1 FY2026: U.S. $2,635,398 thousand, Europe $1,351,744 thousand, Mexico $545,491 thousand
• · Net sales by product Q1 FY2026: Fresh $2,965,392 thousand, Prepared $1,189,825 thousand, Export $254,645 thousand, Other $122,771 thousand
• · Capital expenditures $234,780 thousand in Q1 FY2026
• · Other comprehensive loss of $64,769 thousand in Q1 FY2026, driven by foreign currency translation losses

30-04-2026

Viking Therapeutics reported no revenue for Q1 2026, with research and development expenses surging 263% YoY to $150,150 thousand due to increased clinical activities, resulting in a net loss of $158,325 thousand, more than tripling from $45,629 thousand in Q1 2025. Cash and cash equivalents declined 29% QoQ to $118,116 thousand from $165,810 thousand, driven by $114,000 thousand in operating cash use, though the company raised $12,077 thousand via stock issuances including an ATM offering. Total assets stood at $608,242 thousand with stockholders' equity at $501,917 thousand, reflecting accelerated cash burn but a maintained cash runway.

• · Weighted-average shares for basic and diluted net loss per share: 115,568 thousand in Q1 2026 vs 112,069 thousand in Q1 2025.
• · Basic and diluted net loss per share: $(1.37) in Q1 2026 vs $(0.41) in Q1 2025.
• · Stock-based compensation expense: $10,337 thousand in Q1 2026 vs $11,348 thousand in Q1 2025.
• · ATM offering net proceeds: $11,627 thousand in Q1 2026.

30-04-2026

Meta Platforms reported Q1 2026 revenue of $56,311M, up 33.1% YoY from $42,314M, with net income surging 60.8% YoY to $26,773M driven by strong operating income growth of 30.3% to $22,872M. However, cash and equivalents declined 34.7% QoQ to $23,426M amid elevated capex of $18,997M (up 46.7% YoY) and R&D expenses rising 45.7% YoY to $17,699M, while interest and other expense turned negative at ($1,120M). Operating cash flow increased 34.1% YoY to $32,226M, supporting total assets growth of 8.0% QoQ to $395,250M.

• · Dividends and dividend equivalents declared at $0.525 per share, totaling $1,370M in Q1 2026.
• · Earnings per basic share: $10.57 (Q1 2026) vs. $6.59 (Q1 2025).
• · Net cash used in investing activities: $33,678M in Q1 2026, up from $20,010M YoY.
• · Share-based compensation expense: $6,032M in Q1 2026, up from $4,147M YoY.

30-04-2026

Escalade Inc reported Q1 2026 net sales of $55.8M, nearly flat YoY at +0.6% from $55.5M in Q1 2025. Operating income rose sharply 60% to $5.8M, driven by a 5% decline in cost of goods sold to $38.6M, resulting in net income of $4.4M, up 67% YoY to $0.32 per share. Cash from operations improved to $6.1M from $3.8M, while cash balances grew to $13.1M from $2.2M YoY, though inventories rose 7% QoQ to $73.6M.

• · Current portion of long-term debt increased to $16.7M as of Mar 31 2026 from $7.1M a year ago.
• · Corporate segment reported net loss of $0.3M in Q1 2026, improved from $0.5M loss in Q1 2025.
• · Total assets $227.6M as of Mar 31 2026, up slightly from $222.1M a year ago.
• · Dividends declared $0.15 per share, unchanged YoY.

30-04-2026

PBF Energy Inc. reported a turnaround to net income attributable to stockholders of $198.3 million in Q1 2026 from a $401.8 million loss in Q1 2025, with revenues increasing 11.9% YoY to $7,904.3 million and operating income shifting to $299.6 million from a $511.2 million loss. However, operating cash flow remained negative at $(323.7) million, an improvement from $(661.4) million but still indicative of cash usage, and long-term debt rose QoQ to $2,802.3 million from $2,148.3 million amid higher inventories and receivables. Total assets expanded 13.0% QoQ to $14,718.6 million as of March 31, 2026.

• · Basic EPS $1.69 in Q1 2026 vs $(3.53) in Q1 2025
• · Dividends declared at $0.275 per common share
• · Treasury stock purchases of 181,749 shares for $9.0 million in Q1 2026
• · Equity method investment in SBR increased to $833.4 million from $826.3 million QoQ

30-04-2026

For the three months ended March 31, 2026, StageWise Strategies Corp. reported revenue of $25,249, up 68% YoY from $15,000, with operating expenses declining 38% to $16,693, resulting in net income of $8,556 versus a prior-year loss of $11,980. However, for the six months ended March 31, 2026, revenue fell 36% YoY to $44,467 from $69,690, leading to a net loss of $5,687 compared to a profit of $15,720, while cash and cash equivalents depleted to $0 from $4,573 at period start.

• · 1,000,000 common shares cancelled during six months ended March 31, 2026.
• · Intangible assets decreased to $131,987 from $152,216 as of September 30, 2025.
• · Net cash used in operating activities: $7,206 for six months ended March 31, 2026 (improved from $17,138 prior year).
• · Loan from related parties repaid by $11,779 during six months ended March 31, 2026.

30-04-2026

Bicycle Therapeutics PLC reported collaboration revenue of $887 thousand for Q1 2026, a 91% YoY decline from $9,977 thousand primarily due to no contributions from Novartis and Genentech, while Bayer revenue ticked up slightly to $887 thousand. Operating expenses fell 17% YoY to $66,369 thousand, driven by lower R&D ($48,901 thousand, -17%) and G&A ($17,468 thousand, -17%), resulting in a modestly improved operating loss of $65,482 thousand versus $70,204 thousand prior year. Net loss was nearly flat at $60,825 thousand, with cash and equivalents decreasing QoQ to $559,474 thousand from $628,110 thousand amid $65,925 thousand used in operations (improved from $86,370 thousand YoY).

• · Bayer collaboration deferred revenue ending balance $33,359 thousand as of March 31, 2026.
• · Share-based compensation expense $6,930 thousand for Q1 2026, down from $9,605 thousand YoY.
• · Weighted average ordinary shares outstanding 69,683,471 for Q1 2026.

30-04-2026

Garrett Motion Inc. reported Q1 2026 net sales of $985 million, up 12% YoY from $878 million, with gross profit rising 10% to $196 million and net income surging 53% to $95 million driven by higher sales and operational efficiencies. Operating cash flow strengthened to $98 million from $56 million YoY, but cash and equivalents declined to $142 million from $177 million QoQ amid $87 million in share repurchases and $16 million dividends. SG&A expenses remained flat at $58-59 million YoY, while total liabilities decreased slightly to $3,154 million.

• · Capex expenditures $29 million in Q1 2026 vs $26 million YoY.
• · Accounts receivable increased to $810 million from $703 million QoQ.
• · Accounts payable rose to $1,077 million from $1,061 million QoQ.
• · Total assets stable at $2,373 million vs $2,367 million QoQ.
• · Treasury stock at cost increased to $625 million from $520 million QoQ due to repurchases.

30-04-2026

Phathom Pharmaceuticals reported Q1 2026 product revenue of $58.3M, up 104% YoY from $28.5M, with gross profit rising 87% to $46.3M; net loss narrowed to $30.4M from $94.3M YoY, aided by 43% lower SG&A expenses. Cash and equivalents increased 39% QoQ to $180.9M, bolstered by $122M net proceeds from a public offering and new debt issuance, though offset by $229M debt repayment. However, the company remains unprofitable with operating loss of $15.5M, high total liabilities of $642.1M including $163.7M long-term debt and $347.9M revenue interest financing, and stockholders' deficit of $337.0M.

• · Accounts receivable, net increased to $80.7M from $78.1M QoQ.
• · Total inventory stable at $25.6M vs $26.3M QoQ.
• · Weighted-average shares outstanding: 82,050,618 for Q1 2026 vs 71,969,411 for Q1 2025.
• · Interest paid: $4.9M in Q1 2026 vs $5.2M in Q1 2025.

30-04-2026

For Q1 2026, Cartesian Therapeutics reported total revenues of $78 thousand, down 93% YoY from $1,100 thousand, driven by sharply lower grant income while collaboration revenue remained at zero. Operating expenses rose 16% YoY to $26,577 thousand, with R&D up 33% to $19,463 thousand but G&A down 14% to $7,114 thousand, leading to a widened operating loss of $26,499 thousand (up 21% YoY) and net loss of $39,182 thousand (up 121% YoY, impacted by $13,800 thousand loss on CVR liability). Cash and equivalents fell 5% QoQ to $118,641 thousand despite $15,392 thousand raised via ATM offering, with net cash used in operations improving slightly to $22,135 thousand from $23,108 thousand YoY.

• · Stockholders’ deficit worsened to $(148,118) thousand from $(126,240) thousand QoQ.
• · Contingent value right liability increased $13,800 thousand QoQ to $405,900 thousand.
• · Diluted EPS of $(1.46) for Q1 2026 vs $(0.68) for Q1 2025.
• · Net cash position including restricted cash: $120,376 thousand at March 31, 2026.

30-04-2026

NovoCure reported net revenues of $174,055 thousand for Q1 2026, up 12.3% YoY from $154,994 thousand, with gross profit rising 16.0% to $135,126 thousand. However, operating expenses surged to $202,546 thousand from $154,338 thousand, driven by a 92% increase in general and administrative costs to $85,853 thousand, resulting in a wider operating loss of $67,420 thousand (vs. $37,865 thousand) and net loss of $71,138 thousand (vs. $34,319 thousand). Total assets declined to $787,926 thousand from $804,326 thousand at December 31, 2025, with cash and equivalents at $87,527 thousand.

• · Net cash used in operating activities improved to $13,517 thousand from $35,665 thousand YoY.
• · Share-based compensation expense was $63,009 thousand in Q1 2026 vs. $29,552 thousand in Q1 2025.
• · Senior secured credit facility net remained stable at approximately $195,461 thousand.
• · Trade receivables increased to $93,274 thousand from $89,435 thousand QoQ.

30-04-2026

Kymera Therapeutics reported Q1 2026 collaboration revenue of $34,365 thousand, up 55.5% YoY from $22,100 thousand, reflecting stronger partnership performance. However, research and development expenses increased 22.3% YoY to $98,162 thousand and general/administrative expenses rose 25.1% YoY to $20,357 thousand, driving total operating expenses up 22.8% to $118,519 thousand and widening net loss to $69,234 thousand from $65,581 thousand YoY. Cash and cash equivalents declined sharply 59.6% QoQ to $144,090 thousand from $357,011 thousand, with net cash used in operations at $88,840 thousand.

• · Deferred revenue declined to $0 from $34,365 thousand current and $11,440 thousand non-current as of March 31, 2026.
• · Stock-based compensation expense increased to $16,007 thousand in Q1 2026 from $14,233 thousand YoY.
• · Unrealized loss on marketable securities of $5,994 thousand in Q1 2026, contributing to comprehensive loss of $75,228 thousand.
• · Total cash, cash equivalents, and restricted cash at $149,900 thousand as of March 31, 2026, up YoY from $95,773 thousand.

30-04-2026

Laureate Education reported Q1 2026 revenues of $272,612 up 15.4% YoY from $236,162, driven by strong growth in Peru (+32.2% to $61,954) and Mexico (+11.3% to $210,642). However, operating loss widened significantly to $(27,527) from $(13,191) due to higher direct costs ($289,005 vs $238,363), resulting in a net loss of $(21,594) versus $(19,553) prior year. Cash provided by operating activities improved 7.2% to $61,932, while stockholders' equity declined to $1,048,055 from $1,187,362 amid share repurchases.

• · Direct costs increased 21.4% YoY to $289,005 from $238,363.
• · Accounts and notes receivable, net declined to $55,523 from $134,749 as of Dec 31, 2025.
• · Share repurchases totaled $108,175 in Q1 2026.
• · Long-term debt increased to $160,717 from $73,123 as of Dec 31, 2025.

30-04-2026

Verano Holdings Corp. reported Q1 2026 net revenues of $208.2M, slightly down 0.8% YoY from $209.8M, with gross profit declining 0.6% to $99.0M and operating income falling 12.7% to $13.1M, leading to a widened net loss of $17.8M versus $11.5M in Q1 2025. However, net cash provided by operating activities improved dramatically to $18.6M from $1.8M YoY. Total assets decreased to $1.71B from $1.74B at year-end 2025, with cash and equivalents dropping 10.5% QoQ to $74.0M.

• · SG&A expenses increased 1.5% YoY to $85.9M from $84.6M.
• · Interest expense improved slightly to $12.3M from $13.6M YoY.
• · Capital expenditures (purchases of PPE) were $14.9M in Q1 2026 vs $13.9M in Q1 2025.
• · Financing activities included $195M proceeds from credit facility offset by $240.6M repayments and $5.7M loss on debt extinguishment.

30-04-2026

Bridgewater Bancshares Inc reported robust YoY growth for Q1 2026, with net income rising 80.7% to $17,406 (thousands) from $9,633, net interest income up 21.3% to $36,647 (thousands), and EPS basic at $0.59 versus $0.31, fueled by higher loan interest income (+14.7%) and lower interest expense (-6.1%). However, the securities portfolio declined sharply 27% QoQ to $566,565 (thousands), total assets fell 1.3% QoQ to $5,335,396 (thousands), deposits dipped slightly 0.3% QoQ, and noninterest expenses increased 22.2% YoY to $22,170 (thousands). Provision for credit losses improved to $1,200 (thousands) from $1,500 (thousands) YoY.

• · Net gain on sales of available for sale securities: $7,251 (thousands) in Q1 2026 vs $1 (thousands) in Q1 2025
• · FHLB Advances: $336,000 (thousands) at March 31, 2026 vs $399,500 (thousands) at Dec 31, 2025
• · Allowance for Credit Losses: $57,277 (thousands) at March 31, 2026 vs $56,443 (thousands) at Dec 31, 2025
• · Cash and Cash Equivalents increased $98,643 (thousands) in Q1 2026
• · Proceeds from sales of securities: $208,501 (thousands) in Q1 2026

30-04-2026

Vistance Networks (CommScope Holding) reported net sales from continuing operations of $471.8M for Q1 2026, up 21.6% YoY from $388.1M, with gross profit rising 18.3% to $233.7M and operating income improving to $23.7M from a $16.3M loss, aided by lower R&D expenses. However, income from continuing operations fell 32.1% to $231.7M from $341.1M due to a reduced income tax benefit, while net cash from operations remained negative at $226.6M versus $186.9M used last year. Net income surged to $5,508.0M from $784.0M, driven by $5,276.3M from discontinued operations following a divestiture yielding $10,541.7M in proceeds, which eliminated $7,260.2M in long-term debt and redeemed $1,278.7M in preferred stock.

• · Total assets decreased to $5,443.0M from $9,371.0M QoQ due to divestiture.
• · Stockholders' equity turned positive to $4,594.5M from ($1,004.1M) deficit QoQ.
• · Gain on disposal of discontinued operations: $7,007.9M before tax.
• · Income tax expense on discontinued operations: $1,609.6M Q1 2026 vs benefit $413.8M Q1 2025.
• · Diluted EPS from continuing operations: $0.97 vs $1.25 YoY (decline).

30-04-2026

Altria Group reported Q1 2026 net revenues of $5,428 million, up 3.2% YoY from $5,259 million, with operating income rising 65.3% to $2,956 million and net earnings more than doubling 102.7% to $2,183 million, primarily due to the absence of a $873 million goodwill impairment from the prior year. However, net cash provided by operating activities declined 14.6% YoY to $2,324 million, cash and equivalents fell 21.1% QoQ to $3,531 million from $4,474 million, and total assets decreased 1.2% QoQ to $34,584 million. The company repurchased $280 million in common stock and declared dividends of $1.06 per share.

• · No goodwill impairment in Q1 2026 vs. $873 million in Q1 2025
• · Dividends declared at $1.06 per share in Q1 2026 (vs. $1.02 in Q1 2025)
• · Long-term debt repaid $1,069 million in Q1 2026
• · Stockholders’ equity deficit improved to $(3,161) million from $(3,452) million QoQ

30-04-2026

Fortive Corp reported Q1 2026 total sales of $1,069.4M, up 7.7% YoY from $993.1M, driven by products and software ($860.8M, +7.0%) and services ($208.6M, +10.7%), with operating profit rising 15.9% to $191.7M and net earnings from continuing operations increasing 21.1% to $136.4M. However, total net earnings declined to $136.4M from $171.9M due to the absence of $59.3M discontinued operations earnings from the prior year, while cash and equivalents fell $19.4M to $356.1M and stockholders' equity decreased to $6,091.4M amid $500.2M in share repurchases.

• · Operating cash flow from continuing operations increased to $220.4M from $191.8M YoY.
• · Gross profit margin improved slightly to 63.2% from 64.2% YoY.
• · Long-term debt increased to $2,589.3M as of April 3, 2026 from $2,306.5M at year-end 2025.
• · Net cash used in financing activities was $228.5M, including $591.7M net proceeds from commercial paper.

30-04-2026

InterDigital reported Q1 2026 revenue of $205.4M, down 2% YoY from $210.5M, with Smartphone revenue declining 33% to $123.4M despite a strong 212% increase in CE, IoT/Auto to $81.9M. Net income fell 35% to $75.3M from $115.6M due to a 57% rise in operating expenses to $123.2M. Operating cash flow turned positive at $16.1M, improving from a $20.0M outflow in Q1 2025.

• · Dividends declared per share increased to $0.70 from $0.60 YoY.
• · Accounts receivable rose to $208.3M from $69.8M QoQ.
• · Current portion of long-term debt decreased to $377.8M from $458.4M QoQ.
• · Share repurchases: $8.2M in Q1 2026 vs $5.2M in Q1 2025.

30-04-2026

Butterfly Network reported total revenue of $26,530 thousand for Q1 2026, up 25% YoY from $21,225 thousand, with software and other services surging 68% to $11,877 thousand while product revenue grew modestly 3% to $14,653 thousand. Gross profit rose 37% to $18,285 thousand, and net loss narrowed to $12,677 thousand from $13,967 thousand, reflecting improved operating loss of $13,873 thousand versus $18,468 thousand prior year. However, cash and cash equivalents declined 8% QoQ to $137,954 thousand from $150,489 thousand, with net cash used in operating activities increasing to $13,894 thousand from $11,677 thousand YoY.

• · Weighted-average shares for EPS increased to 256,516,256 in Q1 2026 from 234,923,536 in Q1 2025.
• · Class A common stock issued upon vesting of RSUs: 6,548,354 shares in Q1 2026.
• · Stock-based compensation expense: $5,611 thousand in Q1 2026 versus $6,364 thousand in Q1 2025.
• · Accounts receivable, net: $25,210 thousand as of March 31, 2026, down from $26,744 thousand at December 31, 2025.

30-04-2026

Thryv Holdings, Inc. reported Q1 2026 revenue of $167.7M, down 7.6% YoY from $181.4M, reflecting weaker top-line performance. However, significant cost reductions including a 14.0% drop in operating expenses to $105.2M drove operating income to $4.1M from a $3.0M loss, and net income of $4.5M versus a $9.6M loss YoY. Cash from operations improved to $1.5M from a $10.5M outflow, though cash and equivalents declined to $8.0M as of March 31, 2026.

• · Accounts receivable, net increased to $147.1M from $136.4M QoQ.
• · Term Loan, net decreased to $120.7M from $125.4M QoQ.
• · ABL Facility increased to $29.5M from $25.1M QoQ.
• · Net cash used in investing activities $6.9M, primarily additions to fixed assets and capitalized software.

30-04-2026

FTI Consulting reported Q1 2026 revenues of $983,345 up 9.5% YoY from $898,282, with operating income rising 6.6% to $83,917. However, net income fell 6.8% YoY to $57,631 from $61,824 due to higher interest expense of $6,445 amid increased long-term debt to $754,257, and comprehensive income declined sharply to $47,578 from $76,398 on foreign currency losses. Cash used in operations improved to $310,023 from $465,210 YoY, but cash balances dropped to $198,276 from $265,091 QoQ after $128,202 in share repurchases.

• · Cash and cash equivalents decreased $66,815 QoQ to $198,276 from $265,091.
• · Accrued compensation dropped $342,989 QoQ to $369,346.
• · Total stockholders’ equity declined to $1,661,699 from $1,733,731 QoQ.
• · Accounts receivable, net increased $110,406 QoQ to $1,148,084.
• · Borrowings under revolving line of credit: $590,000; Proceeds from term loan: $300,000 in Q1 2026.

30-04-2026

ConocoPhillips reported Q1 2026 net income of $2,183 million, down 23% YoY from $2,849 million, with sales and other operating revenues declining 5% to $15,761 million from $16,517 million amid higher costs and lower equity earnings. Operating cash flow fell sharply 30% to $4,295 million from $6,115 million, leading to a net cash decrease of $670 million versus a $715 million increase prior year. However, the company sustained capital returns through $1,006 million in share repurchases and $1,032 million in dividends (up from $998 million), with total assets growing to $122,725 million.

• · EPS diluted $1.78 in Q1 2026 vs $2.23 in Q1 2025.
• · Total costs and expenses increased slightly to $12,691 million from $12,635 million YoY.
• · Capital expenditures and investments $2,948 million in Q1 2026 vs $3,378 million prior year.
• · Long-term debt $22,262 million at March 31, 2026, down from $22,424 million at Dec 31, 2025.

30-04-2026

For the three months ended March 31, 2026, Barinthus Biotherapeutics reported a net loss of $5,534 thousand, significantly improved from $19,658 thousand YoY, due to reduced R&D expenses ($3,593 thousand, down 57%) and G&A expenses ($2,528 thousand, down 80%) following January 2025 deprioritization of infectious disease and oncology programs. However, the company continued to burn cash with $3,366 thousand used in operations (vs. $14,902 thousand YoY) and cash and cash equivalents declining to $65,858 thousand from $70,456 thousand at December 31, 2025. Total assets decreased to $92,143 thousand amid ongoing accumulated deficit growth to $309,628 thousand.

• · Share-based compensation expense of $556 thousand in Q1 2026 (up from $468 thousand YoY)
• · Foreign currency translation adjustments contributed $(2,836) thousand to comprehensive loss in Q1 2026 (vs. gain of $4,646 thousand YoY)
• · Net cash provided by investing activities of $55 thousand in Q1 2026 from sale of property and equipment

30-04-2026

For Q1 2026, revenue grew 3.8% YoY to $495,995 from $478,029, driven by higher sales volume, but gross profit was nearly flat at $163,339 (down 0.4%) while SG&A expenses rose 4.0% to $149,709, leading to a 32.2% decline in operating income to $13,630. Net income fell sharply 88.3% to $382 from $3,261, with comprehensive loss of $3,623; cash used in operations worsened to $20,359 from $4,762 amid inventory buildup, offset partially by financing inflows and the $16,241 acquisition of Eastern Valve. Total assets increased to $1,790,004 from $1,748,621, primarily from higher inventories and goodwill.

• · Cash and cash equivalents decreased to $52,729 from $61,753 QoQ.
• · Net cash used in operating activities increased to $20,359 from $4,762 YoY.
• · Business acquisitions used $16,241 in cash during Q1 2026.
• · Foreign currency translation adjustment contributed to $4,005 comprehensive loss.

30-04-2026

Alnylam Pharmaceuticals reported robust Q1 2026 financial results with total revenues of $1,167,175 thousand (up 96% YoY) driven by net product revenues of $1,036,127 thousand (+121% YoY), primarily from AMVUTTRA at $889,931 thousand (+187% YoY), and swung to net income of $205,991 thousand from a $18,251 thousand loss in Q1 2025. Stockholders' equity increased to $1,075,380 thousand (up 36% QoQ). However, ONPATTRO net product revenues declined 59% YoY to $20,481 thousand, while operating cash flow turned positive at $70,504 thousand after a $120,312 thousand use last year.

• · Operating cash flow improved to $70,504 thousand in Q1 2026 from $(120,312) thousand use in Q1 2025.
• · Research and development expenses increased to $364,866 thousand (+38% YoY) from $265,122 thousand.
• · Selling, general and administrative expenses rose to $322,551 thousand (+35% YoY) from $239,949 thousand.
• · Accounts receivable, net increased to $883,957 thousand as of March 31, 2026 from $777,567 thousand at Dec 31, 2025.

30-04-2026

CCC Intelligent Solutions Holdings Inc. reported Q1 2026 revenue of $281,274 up 11.8% YoY from $251,565, with gross profit rising 13.0% to $208,879 and operating income swinging to a profit of $48,817 from a $10,699 loss, driving net income of $15,417 versus a $18,697 loss. However, cash and equivalents dropped sharply 66.8% QoQ to $36,900 from $111,192 due to $100,166 in common stock repurchases, leading to a decline in total assets to $3,470,788 from $3,573,432 and stockholders' equity to $1,721,150 from $1,787,010. Operating cash flow was slightly down 1.8% YoY at $57,461.

• · Weighted-average basic shares: 587,380,660 (Q1 2026) vs 636,832,216 (Q1 2025)
• · Total operating expenses declined to $160,062 from $195,691 YoY due to lower R&D ($52,524 vs $61,763), selling & marketing ($39,418 vs $48,297), and G&A ($49,608 vs $67,119)
• · EvolutionIQ acquisition in Q1 2025: total purchase price $674,267 (historical)
• · Note payable to minority investor increased to $25,953 from $25,197 QoQ